|
Randy Gascoyne, M.D. is a Hematopathologist at the BC Cancer Agency in Vancouver and the sole Canadian member of the international lymphoma study group (ILSC). He received his B.S. in Microbiology and M.D. at the University of Columbia. Dr. Gascoyne has expertise in lymphoma diagnosis and classification, molecular genetics of lymphoma and pathogenesis. He is professor of Pathology at the University of British Columbia.
His career spans 17 years as a lymphoma pathologist, with excellence in diagnostic pathology and translational research. He has published more than 275 papers and abstracts, has authored several chapters in sub-speciality books and is currently writing the next edition of the Armed Forces Institute of Pathology Fascicle on Tumors of the Lymph Nodes & Spleen together with Dr. Wing Chan of Nebraska and Dr. John Chan of Hong Kong. He is on the editorial board of several high-ranking speciality journals and serves as an expert reviewer for more than 20 journals in the field of neoplastic Hematopathology. Dr Gascoyne currently holds more than $1,000,000/year in research funding investigating the pathogenesis of NHLs. He is also the head of the BC team of investigators recently awarded a 3-year grant from LRF to study new molecular targets in Mantle Cell.
His research interests include molecular alterations that characterize lymphomagenesis, biomarker analyses in non-Hodgkin's lymphomas (NHL) and their use as outcome predictors and gene expression microarray.
|
